8-K: Concentra Previews Strong Q4, FY25 Results at JPM Conference

Concentra Group Holdings Parent, Inc. announced preliminary, unaudited Q4 and full-year 2025 operational metrics and financial guidance, ahead of its presentation at the J.P. Morgan Healthcare Conference.

Summary

• Preliminary, unaudited Q4 2025 operational metrics and full-year 2025 financial guidance were published.
• The company expects FY 2025 revenue between $2.145 billion and $2.160 billion.
• Adjusted EBITDA for FY 2025 is projected to be between $425 million and $430 million.
• Year-over-year growth in revenue and Adjusted EBITDA was +13% as of YTD September 2025.
• Q4 2025 visits per day (excluding Nova) increased by +3.4% for Workers Compensation and +2.3% for Employer Services year-over-year.
• Total Company Q4 2025 visits per day increased by +9.1% for Workers Compensation and +9.4% for Employer Services year-over-year.
• The company repurchased approximately 1.1 million shares in Q4 2025.
• Net leverage is 3.6x as of Q3 2025, with high visibility to 3.5x by year-end 2025 and <3.0x by year-end 2026.
• The company maintains a stable, growing margin profile at approximately 20% Adjusted EBITDA margin.
• A long track record of >100% Free Cash Flow conversion, with nearly $1 billion of free cash flow since 2021.
• Strong, consistently increasing mid-teens ROIC with an attractive ROIC/WACC ratio.
• Commitment to returning capital to shareholders through a dividend (~1.3% yield) and a $100 million share buyback program.

Sentiment

Score: 8

Explanation: The filing presents strong preliminary financial results and guidance, positive operational metrics, and a clear strategy for growth and shareholder returns. The company highlights its market leadership, diversified revenue, and favorable industry trends. While general forward-looking statement risks are noted, no specific negative operational or financial issues are disclosed.

Positives

• Strong preliminary FY 2025 guidance: Revenue $2.145bn $2.160bn and Adjusted EBITDA $425mm $430mm.
• Robust year-over-year growth: +13% in Revenue and Adjusted EBITDA (YTD Sep. 2025).
• Positive Q4 2025 visit growth: Workers Compensation +9.1% and Employer Services +9.4% (Total Company).
• Significant share repurchase: ~1.1 million shares bought back in Q4 2025.
• Improving leverage: 3.6x net leverage (Q3 2025) with a target of <3.0x by year-end 2026.
• Stable and growing Adjusted EBITDA margin at ~20%.
• Strong Free Cash Flow generation: >100% FCF conversion and nearly $1 billion since 2021.
• Attractive Return on Invested Capital (ROIC) in the mid-teens.
• Diversified business model with <1% revenue from government payors and <3% from the largest employer customer.
• History of robust strategic growth with over 70 acquisitions and de novos since 2016.
• Secular tailwinds supporting market growth, including an aging workforce, reshoring, and the AI economy.

Risks

• Actual results may differ materially from forward-looking statements due to various important factors.
• Factors are detailed in the company's Annual Report on Form 10-K for the year ended December 31, 2024, filed on March 3, 2025, and other SEC filings under "Risk Factors" and "Forward-Looking Statements."
• Changes in global, regional, or local economic, business, competitive, market, regulatory, and other factors, many of which are beyond the company's control.
• The company does not undertake any obligation to update or revise any forward-looking statements, except as required by law.

Future Outlook

The company anticipates providing Q4 and FY 2025 flash results, 2026 guidance, and a comprehensive investor book in late January. A regularly scheduled Q4 earnings call is planned for late February. The company also has high visibility into achieving net leverage of 3.5x by year-end 2025 and less than 3.0x by year-end 2026.

Industry Context

The company operates as the largest provider of occupational health services in the U.S., treating approximately 1 in every 4 workplace injuries. It benefits from secular tailwinds such as an aging workforce leading to more severe workers' compensation injuries, reshoring driving job growth in manufacturing and construction, and the AI economy creating new jobs and power build-out needs. The company's fee-for-service rates have averaged a 3% CAGR over a 10-year period, largely tracking inflationary indices, indicating resilience against broader economic pressures.

Comparison to Industry Standards

• The company is the largest provider of occupational health services in the U.S. by number of locations, with over 10x the size of its next largest pure-play occupational health competitor.
• Claim studies conducted by the company show a 25% average lower cost per claim compared to competitors, based on approximately 500,000 closed claims evaluated between 2020 and 2023 for select customers.
• The company's fee-for-service rates have averaged a 3% CAGR over a 10-year period, which largely tracks inflationary indices, suggesting a strong pricing power relative to industry trends.
• The company's diversified revenue streams, with <1% from government payor reimbursement and <3% from its largest employer customer, indicate a lower risk profile compared to companies heavily reliant on specific payors or large clients.
• The company's average <3x pro forma EBITDA multiple across all bolt-on M&A deals and de novos since 2016 suggests efficient capital deployment for growth compared to typical industry acquisition multiples.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, share buyback program, dividend yield (~1.3%), and commitment to reducing leverage.
• Employees/Clinicians: The company has ~13k total colleagues & affiliated clinicians, suggesting a stable and growing workforce given the company's expansion.
• Customers (Employers): The company serves ~200k employer customers, including 100% of Fortune 100 companies, and claims demonstrable outcomes with 25% lower cost per claim and 80% patient satisfaction (9 or 10 out of 10).
• Patients: 80% of patients rate the company 9 or 10 out of 10, indicating high satisfaction with services.

Next Steps

• Provide Q4 and FY 2025 flash results in late January.
• Provide 2026 guidance in late January.
• Publish a comprehensive investor book (Concentra and industry primer) in late January.
• Hold a regularly scheduled Q4 earnings call in late February.
• Continue efforts to reduce net leverage to 3.5x by year-end 2025 and below 3.0x by year-end 2026.

Key Dates

Recommendation

The company is demonstrating robust financial health with strong preliminary FY 2025 results and positive guidance, indicating continued growth in revenue and Adjusted EBITDA. Operational metrics show significant year-over-year visit growth. The commitment to shareholder returns through a dividend and a substantial share buyback program, coupled with a clear path to reduced leverage, makes the stock highly attractive. Its market leadership, diversified business model, and favorable industry tailwinds further strengthen its investment profile, suggesting a 'strong buy' for long-term investors.

Keywords

Occupational Health, Healthcare Services, SEC Filing, 8-K, Investor Presentation, Financial Results, Q4 2025, FY 2025 Guidance, J.P. Morgan Healthcare Conference, CON, Concentra, Workplace Health, Workers Compensation, Employer Services, Adjusted EBITDA, Free Cash Flow, Share Buyback